Literature DB >> 11284050

Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6beta-hydroxylase.

D Dai1, R Bai, E Hodgson, R L Rose.   

Abstract

A full-length cDNA clone encoding a novel form of the cytochrome P450 3A subfamily (Cyp3a-25) has been isolated from a mouse liver cDNA library. The sequence contained 2010 base pairs and encoded a protein with 503 amino acids. The amino acid sequence shared greater identities with rat CYP3A18 (90%) and golden hamster CYP3A10 (81%) sequences than with known mouse sequences (Cyp3a-11, Cyp3a-13, Cyp3a-16, and Cyp3a-41 [68--70%]). CYP3A25 was expressed in the Escherichia coli PCWori(+) expression vector following slight modifications of the N- and C-terminals of the cDNA. The purified CYP3A25 was recognized on an immunoblot by CYP3A1 antibody and has a molecular weight of 50 kD. CYP3A25 was catalytically active in the 6 beta-hydroxylation of testosterone and the N-demethylation of benzphetamine and erythromycin. It was demonstrated by RT-PCR that the CYP3A25 mRNA is present in both fetal and adult tissues, including liver, lung, intestines, kidney, and brain. Northern blotting demonstrated that expression is greatest in the liver and small intestine. Copyright 2001 John Wiley & Sons, Inc. J Biochem Mol Toxicol 15:90-99, 2001

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284050     DOI: 10.1002/jbt.4

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  8 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

2.  Transplacental exposure to inorganic arsenic at a hepatocarcinogenic dose induces fetal gene expression changes in mice indicative of aberrant estrogen signaling and disrupted steroid metabolism.

Authors:  Jie Liu; Yaxiong Xie; Ryan Cooper; Danica M K Ducharme; Raymond Tennant; Bhalchandra A Diwan; Michael P Waalkes
Journal:  Toxicol Appl Pharmacol       Date:  2007-02-06       Impact factor: 4.219

3.  Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study.

Authors:  Junhui Su; Cui Chang; Qi Xiang; Zhi-Wei Zhou; Rong Luo; Lun Yang; Zhi-Xu He; Hongtu Yang; Jianan Li; Yu Bei; Jinmei Xu; Minjing Zhang; Qihao Zhang; Zhijian Su; Yadong Huang; Jiyan Pang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-12-12       Impact factor: 4.162

4.  Effect of the active ingredient of Kaempferia parviflora, 5,7-dimethoxyflavone, on the pharmacokinetics of midazolam.

Authors:  Wataru Ochiai; Hiroko Kobayashi; Satoshi Kitaoka; Mayumi Kashiwada; Yuya Koyama; Saho Nakaishi; Tomomi Nagai; Masaki Aburada; Kiyoshi Sugiyama
Journal:  J Nat Med       Date:  2018-03-17       Impact factor: 2.343

Review 5.  Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy.

Authors:  Megha Gautam; Ganesh Thapa
Journal:  Acta Neurol Belg       Date:  2020-08-02       Impact factor: 2.396

Review 6.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Tissue Distribution and Gender-Specific Protein Expression of Cytochrome P450 in five Mouse Genotypes with a Background of FVB.

Authors:  Jiamei M Chen; Qisong S Zhang; Xiaoyan Y Li; Xia Gong; Yanjiao J Ruan; Sijing J Zeng; Linlin L Lu; Xiaoxiao X Qi; Ying Wang; Ming Hu; Lijun J Zhu; Zhongqiu Q Liu
Journal:  Pharm Res       Date:  2018-04-10       Impact factor: 4.200

8.  Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course.

Authors:  Huixia Zhang; Xiaohui Wu; Honggang Wang; Andrei M Mikheev; Qingcheng Mao; Jashvant D Unadkat
Journal:  Mol Pharmacol       Date:  2008-05-28       Impact factor: 4.054

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.